Presentation is loading. Please wait.

Presentation is loading. Please wait.

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years  Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Published byKristina Viken Modified over 5 years ago

Similar presentations

Presentation on theme: "Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years  Charles A. Yankah, MD, PhD, Miralem Pasic, MD,"— Presentation transcript:

1 Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years  Charles A. Yankah, MD, PhD, Miralem Pasic, MD, PhD, Michele Musci, MD, Julia Stein, MSc, Christine Detschades, SRN, Henryk Siniawski, MD, PhD, Roland Hetzer, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 136, Issue 3, Pages (September 2008) DOI: /j.jtcvs Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 Overall cumulative survival of all 1513 patients after aortic valve replacement and of a German population as background (data from Federal Bureau for Population Statistics, Wiesbaden, Germany). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Actuarial freedom from reoperation for structural valve deterioration (SVD) in age groups (50–59, 60–69, and ≥70 years) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Actual (cumulative incidence) freedom from reoperation for structural valve deterioration (SVD) by age group (50–59, 60–69 and ≥70 years) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 Actuarial and actual (cumulative incidence) freedom from reoperation for structural valve deterioration (SVD) in age group ≥65 years after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

6 Figure 5 Time-related transvalvular mean gradients in relation to labeled valve sizes. Each symbol represents a labeled valve size. Solid lines represent time-related estimates of median values for each prosthesis. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

7 Figure 6 Actuarial freedom from thromboembolism (TE) after pericardial aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

8 Figure 7 Hazard function of prosthetic valve endocarditis after pericardial aortic valve replacement. Constant hazard rate of events. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2008 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years  Charles A. Yankah, MD, PhD, Miralem Pasic, MD,"

Similar presentations

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,
W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Of mice and men and surgical transcatheter aortic valve insertion

Of mice and men and surgical transcatheter aortic valve insertion
Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years  John B. Chambers, MD, FRCP,

Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years  John B. Chambers, MD, FRCP,
The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

The fate of small-size pericardial heart valve prostheses in an older patient population  Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,
Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters  Victor Dayan, MD, PhD, Philippe Pibarot,

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters  Victor Dayan, MD, PhD, Philippe Pibarot,
Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,
Very Long-Term Outcomes of the Carpentier-Edwards Perimount Aortic Valve in Patients Aged 60 or Younger  Thierry Bourguignon, MD, Rym El Khoury, MD, Pascal.

Very Long-Term Outcomes of the Carpentier-Edwards Perimount Aortic Valve in Patients Aged 60 or Younger  Thierry Bourguignon, MD, Rym El Khoury, MD, Pascal.
Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R

Scott Goldman, MD, Anson Cheung, MD, Joseph E. Bavaria, MD, Michael R
Sergey Leontyev, MD, Michael A

Sergey Leontyev, MD, Michael A
Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H

Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H
In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.

In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.
Fate of aortic bioprostheses: An 18-year experience

Fate of aortic bioprostheses: An 18-year experience
Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,
Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E

Harald C. Eichstaedt, MD, Jerry Easo, MD, Tobias Härle, MD, Otto E
Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards.

Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards.
Long-term prognosis of ascending aortic aneurysm after aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis  Evaldas Girdauskas,

Long-term prognosis of ascending aortic aneurysm after aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis  Evaldas Girdauskas,
When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 

When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 
Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,

Similar presentations

Ads by Google